Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]

  • Topic selection

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators